Experiences with
Obinutuzumab377 public posts
Chemo-free treatment with acalabrutinib can benefit CLL/SLL patients never treated before: a plain language summary of the ELEVATE-TN study
obinutuzumab would be alive without disease getting worse 4 years after starting treatment compared with only 25% of patients who had the usual chemoimmunotherapy option of obinutuzumab plus chlorambucil.
Want to take advantage of all our features? Just log in!
or
New Greek consensus statement for the treatment of chronic lymphocytic leukemia
median OS was not reached in any treatment arm and was considerably longer in patients treated with Acalabrutinib-Obinutuzumab versus Obinutuzumab-Chlorambucil combination.¹⁸ However, patients in the Acalabrutinib-Obinutuzumab arm experienced more frequently grade ≥3 adverse